EUnetHTA has published the second iteration of the EUnetHTA Prioritisation List (EPL). The EPL expresses the identified significant interest of national HTA bodies in relation to individual compounds as presented in the list. By proactively selecting those topics in direct collaboration with national bodies, EUnetHTA strives to increase the implementation of Joint Assessments at the national level. This is one of the key elements of Joint Action 3.
The EPL is published as part of the overarching Topic Identification, Selection and Prioritisation (TISP) task group. The topics identified and prioritised in the first EPL remain relevant and valid.
Topics have been identified through horizon scanning activities and via feedback from EMA and EUnetHTA partners. Selection and prioritisation are based on four criteria:
Attaining the EPL listing demonstrates a significant degree of interest on the part of HTA bodies in receiving a Joint Relative Efficacy Assessment (REA) on the specific topic. EUnetHTA will, therefore, engage with all companies on the EPL in order to establish further dialogue to increase the opportunities for collaboration on prioritised topics.
* EUnetHTA JA3 will not be accepting any further Letters of Intent with regard to new pharma Joint Assessments through the end of Joint Action 3 on 31st May, 2021.For further information please contact:
Olaparib is indicated as monotherapy maintenance treatment for gBRCAm metastatic pancreatic cancer patients whose disease has not progressed on first line platinum based chemotherapy
Acronym List for EPL
IMA – Initial Market Application
EoI – Extension of Indication
AC – Accelerated Access
OD – Orphan Designation
PRIME – Priority Medicine
ATMP – Advanced Therapy Medicinal Product
*Originally prioritised compound: ribociclib+fulvestrant for advanced HR-positive, HER2-negative breast cancer in postmenopausal women – first or second line.
**Originally prioritised compound: ribociclib+alpelisib+fulverstrant for HR-positive, HER2-negative postmenopausal breast cancer – second or third line.
This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.
©2021 EUnetHTA All rights reserved.